Cover Image
Market Research Report

Opioid Drugs: Global Markets to 2023

Published by BCC Research Product code 750754
Published Content info 147 Pages
Delivery time: 1-2 business days
Price
Back to Top
Opioid Drugs: Global Markets to 2023
Published: November 29, 2018 Content info: 147 Pages
Description

Report Highlights:

The global market for opioid drugs should reach $29.8 billion by 2023 from $26.4 billion in 2018 at a compound annual growth rate (CAGR) of 2.5% for the period of 2018-2023.

The buprenorphine drug segment of the global opioid drugs market is expected to grow from $5.1 billion in 2018 to $6.3 billion in 2023 at a CAGR of 4.4% for the period of 2018-2023.

The morphine drug segment of the global opioid drugs market is expected to grow from $5.0 billion in 2018 to $5.7 billion in 2023 at a CAGR of 2.7% for the period of 2018-2023.

Report Scope:

The current report offers a detailed picture of the prescription opioid drug market. Prescription opioids are included in the scope of study; illegal opioids such as heroin, which are sold in illegal market for illicit usage, are not included. The market estimation includes all branded and generic opioid drugs indicated for different therapeutic application such as pain management and opioid use disorders.

This report highlights the current and future market potential of opioid drugs along with detailed analyses of the competitive environment, regulatory scenario, pipeline analysis, technological advancement and market dynamics.

The report details market shares of opioid drugs based on product and geography. Based on product, the market is segmented into buprenorphine, fentanyl, hydrocodone, morphine, oxycodone, tramadol and others. Each product segment includes detailed analyses covering an overview of drug, mechanism of action and market insights on each drug.

By geography, the market has been segmented into North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. Detailed analyses of major countries such as the U.S., Germany, the U.K. France, Japan, China and India are covered in regional segments. For market estimates, data has been provided for the year 2017 and the base year of 2018 and forecast for 2023. Estimated values used are based on drug manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Report Includes:

  • 20 data tables and 38 additional tables
  • An overview of the global market for opioid drugs
  • Analyses of global market trends, with data from 2017 to 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Discussion of types, mode of action and receptor target of opioids drugs i.e. Mu receptor, Delta receptor and Kappa receptor
  • Details of technological advancement for new opioid formulation to reduce the risk of drug abuse
  • Case study of opioid addiction, opioid abuse and overdose and significant events addressing opioid misuse and abuse
  • Information on stringent regulatory policies and government guidelines to impede the adoption rate of the opioid drugs
  • Insights of new safety measures announced for immediate release (IR) opioids and CDC guidelines on prescribing opioids for chronic pain
  • Company profiles of the major players of the market, including Acura Pharmaceuticals Inc., Cipher Pharmaceutical Inc., Daiichi Sankyo Inc., Johnson & Johnson, Lupin Ltd., Pfizer Inc., Sun Pharmaceuticals and Teva Pharmaceutical Industries Ltd.
Table of Contents
Product Code: PHM207A

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

  • Overview: Opioid Drugs
  • Types of Opioids
  • Receptor Targets of Opioid Drugs
    • Mu Receptor
    • Delta Receptor
    • Kappa Receptor
  • Significant Events Related to Opioid Misuse and Abuse
  • Technology Advancements in Opioid Drugs
    • Abuse Deterrent Approaches
    • Abuse-Deterrent Technologies
    • Novel Drug Delivery Systems
  • Therapeutic Applications of Opioid Drugs
    • Cancer Pain Management
    • Surgical Pain Management
    • Opioid Use Disorder
  • Prescription Drug Monitoring Programs (PDMPs)

Chapter 4: Market Dynamics

  • Market Drivers
    • Rising Prevalence of Chronic Pain
    • Rise in Palliative Care for Patients Suffering from Pain
    • New Opioid Formulation to Reduce the Risk of Abuse
    • Increasing Incidence of Road Accidents and Surgical Procedures
  • Market Restraints
    • Widespread Misuse of Opioids
    • Increasing Incidence of Death Related to Opioid Overdose
    • Growing Number of Lawsuits against Opioid Manufacturers

Chapter 5: Market Breakdown by Product

  • Global Market for Opioid Drugs by Product
  • Buprenorphine
    • Market Size and Forecast
    • Market Analysis
  • Fentanyl
    • Market Size and Forecast
    • Market Analysis
  • Hydrocodone
    • Market Size and Forecast
    • Market Analysis
  • Morphine
    • Market Size and Forecast
    • Market Analysis
  • Oxycodone
    • Market Size and Forecast
    • Market Analysis
  • Tramadol
    • Market Size and Forecast
    • Market Analysis
  • Others
    • Market Size and Forecast
    • Market Analysis

Chapter 6: Market Breakdown by Region

  • Global Market for Opioid Drugs by Region
  • North America
    • United States
    • Canada and Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • South America
    • Market Size and Forecast
    • Market Analysis
  • Middle East and Africa
    • Market Size and Forecast
    • Market Analysis

Chapter 7: Regulatory Environment

  • Regulations in the U.S.
    • New Drug Approvals
    • The FDA Modernization Act of 1997
  • New Safety Measures for Immediate-Release (IR) and Extended-Release (ER) Formulations
    • Risk Evaluation and Mitigation Strategy (REMS)
  • Schedules Under the Controlled Substances Act
  • Federal Initiatives to Address Non-medical Use of Prescription Opioids
  • FDA's Opioid Policy Work Plan
  • CDC Guidelines for Prescribing Opioids for Chronic Pain

Chapter 8: Pipeline Analysis

  • Overview of the Drug Development Process
  • Pipeline Analysis of Opioid Drugs

Chapter 9: Competitive Landscape

  • Current Market Scenario
    • Key Strategies Adopted by Market Players
    • Influence of Generic Drugs on the Global Opioid Drug Market
    • Significant Industry Events and Developments

Chapter 10: Company Profiles

  • ACURA PHARMACEUTICALS INC.
    • Company Overview
    • Product Portfolio
  • ALLERGAN PLC
    • Company Overview
    • Financials
    • Product Portfolio
  • APOTEX INC.
    • Company Overview
    • Product Portfolio
  • ASSERTIO THERAPEUTICS INC. (DEPOMED INC.)
    • Company Overview
    • Financials
    • Product Portfolio
    • Developments and Strategies
  • BIODELIVERY SCIENCES INTERNATIONAL INC.
    • Company Overview
    • Financials
    • Product Portfolio
    • Developments and Strategies
  • CIPHER PHARMACEUTICALS INC.
    • Company Overview
    • Product Portfolio
  • COLLEGIUM PHARMACEUTICAL INC.
    • Company Overview
    • Product Portfolio
  • DAIICHI SANKYO INC.
    • Company Overview
    • Product Portfolio
  • EGALET CORP.
    • Company Overview
    • Product Portfolio
  • ENDO INTERNATIONAL PLC
    • Company Overview
    • Financials
    • Product Portfolio
    • Developments and Strategy
  • HIKMA PHARMACEUTICALS PLC
    • Company Overview
    • Product Portfolio
  • INDIVIOR PLC
    • Company Overview
  • INSYS THERAPEUTICS INC.
    • Company Overview
    • Product Portfolio
  • JOHNSON & JOHNSON
    • Company Overview
    • Product Portfolio
  • KEMPHARM INC.
    • Company Overview
    • Product Portfolio
  • LANNETT CO. INC.
    • Company Overview
    • Financials
    • Product Portfolio
  • LUPIN LTD.
    • Company Overview
    • Product Portfolio
  • MALLINCKRODT
    • Company Overview
    • Product Portfolio
  • MYLAN NV
    • Company Overview
    • Financials
    • Product Portfolio
    • Developments and Strategies
  • OREXO AB
    • Company Overview
    • Product Portfolio
  • PFIZER INC.
    • Company Overview
    • Product Portfolio
    • Developments and Strategies
  • PURDUE PHARMA LP
    • Company Overview
    • Product Portfolio
    • Developments and Strategies
  • PERNIX THERAPEUTICS
    • Company Overview
    • Product Portfolio
    • Developments and Strategies
  • SUN PHARMACEUTICAL INDUSTRIES LTD. (SUN PHARMA)
    • Company Overview
    • Financials
    • Product Portfolio
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • Company Overview
    • Financials
    • Product Portfolio

Chapter 11: Appendix: Acronyms

List of Tables

  • Summary Table: Global Opioid Drug Market, by Product, Through 2023
    • Table 1: Analgesic Effects of Drugs at Different Opioid Receptors
    • Table 2: Timeline of Selected FDA Activities and Events Related to Opioid Misuse and Abuse, 1911-2018
    • Table 3: FDA Approved Opioids with ADF Labeling
    • Table 4: Opioid Lawsuit Settlements, 2015-2027
    • Table 5: Global Opioid Drug Market, by Product, Through 2023
    • Table 6: Global Buprenorphine Drug Market, by Region, Through 2023
    • Table 7: Global Fentanyl Drug Market, by Region, Through 2023
    • Table 8: Global Hydrocodone Drug Market, by Region, Through 2023
    • Table 9: Global Morphine Drug Market, by Region, Through 2023
    • Table 10: Global Oxycodone Drug Market, by Region, Through 2023
    • Table 11: Global Tramadol Drug Market, by Region, Through 2023
    • Table 12: Global Market for Other Types of Opioid Drugs, by Region, Through 2023
    • Table 13: Global Opioid Drug Market, by Region, Through 2023
    • Table 14: North American Opioid Drug Market, by Product, Through 2023
    • Table 15: North American Opioid Drug Market, by Country, Through 2023
    • Table 16: Number of Prescriptions for Six of the Most Frequently Prescribed Opioids in Canada, 2012-2016
    • Table 17: European Opioid Drug Market, by Product, Through 2023
    • Table 18: European Opioid Drug Market, by Country, Through 2023
    • Table 19: Asia-Pacific Opioid Drug Market, by Product, Through 2023
    • Table 20: Asia-Pacific Opioid Drug Market, by Country, Through 2023
    • Table 21: South American Opioid Drug Market, by Product, Through 2023
    • Table 22: Middle East and African Opioid Drug Market, by Product, Through 2023
    • Table 23: List of ER/LA Opioid Drugs Subject to Opioid REMS, Branded Drugs, 2017
    • Table 24: List of ER/LA Opioid Drugs Subject to Opioid REMS, Generic Drugs, 2017
    • Table 25: Schedules Under the Controlled Substances Act
    • Table 26: Recent Initiatives to Control the Opioid Crisis in the U.S., 2018
    • Table 27: CDC Guidelines on Prescribing Opioids
    • Table 28: Opioid Drug Pipeline
    • Table 29: R&D Expenditures of Market Players, 2017
    • Table 30: Number of FDA Approvals (NDA and ANDA), 2005-2015
    • Table 31: Significant Industry Events in the Opioid Drug Market, 2015-2018
    • Table 32: Acura Pharmaceuticals: Opioid Drug Product Portfolio
    • Table 33: Allergan Plc: Opioid Drug Product Portfolio
    • Table 34: Apotex Inc.: Opioid Drug Product Portfolio
    • Table 35: Assertio Therapeutics: Opioid Drug Product Portfolio
    • Table 36: Biodelivery Sciences International Inc.: Opioid Drugs Product Portfolio
    • Table 37: Cipher Pharmaceuticals Inc.: Opioid Drugs Product Portfolio
    • Table 38: Collegium Pharmaceutical Inc.: Opioid Drug Product Portfolio
    • Table 39: Daiichi Sankyo Inc.: Opioid Drug Product Portfolio
    • Table 40: Egalet Corp.: Opioid Drugs Product Portfolio
    • Table 41: Endo International Plc: Opioid Drugs Product Portfolio
    • Table 42: Hikma Pharmaceuticals Plc: Opioid Drugs Product Portfolio
    • Table 43: Indivior Plc: Opioid Drug Product Portfolio
    • Table 44: Insys Therapeutics Inc.: Opioid Drug Product Portfolio
    • Table 45: Johnson & Johnson: Opioid Drug Product Portfolio
    • Table 46: KemPharm Inc.: Opioid Drugs Product Portfolio
    • Table 47: Lannett Co. Inc.: Opioid Drug Product Portfolio
    • Table 48: Lupin Ltd.: Opioid Drug Product Portfolio
    • Table 49: Mallinckrodt: Opioid Drug Product Portfolio
    • Table 50: Mylan NV: Opioid Drug Product Portfolio
    • Table 51: Orexo AB: Opioid Drug Product Portfolio
    • Table 52: Pfizer Inc.: Opioid Drugs Product Portfolio
    • Table 53: Purdue Pharma LP: Opioid Drug Product Portfolio
    • Table 54: Pernix Therapeutics: Opioid Drug Product Portfolio
    • Table 55: Sun Pharmaceuticals Industries Ltd.: Opioid Drugs Product Portfolio
    • Table 56: Teva Pharmaceutical Industries Ltd.: Opioid Drug Product Portfolio
    • Table 57: Acronyms Used in This Report

List of Figures

  • Summary Figure: Global Opioid Drug Market Share, by Product, 2017
    • Figure 1: Opioid Misuse Among People 12 or Older, by Age Group, 2015
    • Figure 2: Prescription Pain Relief Misuse Among People 12 or Older, by Age Group, 2015
    • Figure 3: Number of Drug Overdose Deaths in the U.S., 2010-2016
    • Figure 4: Global Opioid Drug Market Share, by Product, 2017
    • Figure 5: Global Buprenorphine Drug Market, 2017-2023
    • Figure 6: Global Buprenorphine Drug Market, by Region, 2017-2023
    • Figure 7: Global Fentanyl Drug Market, 2017-2023
    • Figure 8: Global Fentanyl Drug Market, by Region, 2017-2023
    • Figure 9: Global Hydrocodone Drug Market, 2017-2023
    • Figure 10: Global Hydrocodone Drug Market, by Region, 2017-2023
    • Figure 11: Global Morphine Drug Market, 2017-2023
    • Figure 12: Global Morphine Drug Market, by Region, 2017-2023
    • Figure 13: Global Oxycodone Drug Market, 2017-2023
    • Figure 14: Global Oxycodone Drug Market, by Region, 2017-2023
    • Figure 15: Global Tramadol Drug Market, 2017-2023
    • Figure 16: Global Tramadol Drug Market, by Region, 2017-2023
    • Figure 17: Global Market for Other Types of Opioid Drugs, 2017-2023
    • Figure 18: Global Market for Other Types of Opioid Drugs, by Region, 2017-2023
    • Figure 19: Global Opioid Drug Market Share, by Region, 2017
    • Figure 20: North American Opioid Drug Market Share, by Product, 2017
    • Figure 21: North American Opioid Drug Market Share, by Country, 2017
    • Figure 22: U.S. Opioid Drug Market, 2017-2023
    • Figure 23: Total Number of Opioid Prescriptions Dispensed, U.S, 2010-2017
    • Figure 24: Number of Drug Overdose Deaths, U.S., 2010-2016
    • Figure 25: Canadian and Mexican Market for Opioid Drugs, 2017-2023
    • Figure 26: European Opioid Drug Market Share, by Product, 2017
    • Figure 27: European Opioid Drug Market Share, by Country, 2017
    • Figure 28: German Opioid Drug Market, 2017-2023
    • Figure 29: U.K. Opioid Drug Market, 2017-2023
    • Figure 30: French Opioid Drug Market, 2017-2023
    • Figure 31: Rest of European Market for Opioid Drugs, 2017-2023
    • Figure 32: Asia-Pacific Opioid Drug Market Share, by Product, 2017
    • Figure 33: Asia-Pacific Opioid Drug Market Share, by Country, 2017
    • Figure 34: Japanese Opioid Drug Market, 2017-2023
    • Figure 35: Chinese Opioid Drug Market, 2017-2023
    • Figure 36: Indian Opioid Drug Market, 2017-2023
    • Figure 37: Rest of Asia-Pacific Opioid Drug Market, 2017-2023
    • Figure 38: South American Opioid Drug Market, 2017-2023
    • Figure 39: South American Opioid Drug Market Share, by Product, 2017
    • Figure 40: Middle East and African Market for Opioid Drugs, 2017-2023
    • Figure 41: Middle East and African Opioid Drug Market Share, by Product, 2017
    • Figure 42: Allergan Plc: Annual Revenue, 2013-2017
    • Figure 43: Allergan Plc: Revenue Share, by Business Unit, 2017
    • Figure 44: Assertio Therapeutics: Revenue, 2013-2017
    • Figure 45: Biodelivery Sciences International Inc.: Annual Revenue, 2013-2017
    • Figure 46: Endo International Plc: Revenue, 2013-2017
    • Figure 47: Endo International Plc: Revenue Share, by Business Unit, 2017
    • Figure 48: Lannett Co. Inc.: Financial Performance, 2015-2017
    • Figure 49: Mylan NV: Financial Performance, 2014-2017
    • Figure 50: Mylan NV: Revenue Share, by Region, 2017
    • Figure 51: Sun Pharmaceuticals Industries Ltd.: Financial Performance, 2015-2017
    • Figure 52: Teva Pharmaceutical Industries Ltd.: Financial Performance, 2015-2017
    • Figure 53: Teva Pharmaceutical Industries Ltd.: Revenue Share, by Region, 2017
    • Figure 54: Teva Pharmaceutical Industries Ltd.: Revenue Share, by Business Segment, 2016
Back to Top